Viridian Therapeutics is focused on advancing new treatments for patients with diseases that are underserved by today’s therapies. Our lead candidate, VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) we are developing and intend to commercialize for the potential treatment for patients with thyroid eye disease (TED), a debilitating condition that significantly impacts quality of life and can cause proptosis (“bulging eyes”), double vision and potential blindness.

More than 100 oncology patients have previously been treated with the antibody, under the name AVE-1642, in US and EU studies sponsored by Sanofi, enabling some understanding of its pharmacokinetic and pharmacodynamic profile, as well as its safety and tolerability.

Worldwide rights to develop and commercialize VRDN-001 for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of TED, were exclusively licensed by Viridian from ImmunoGen, Inc.